“…S. Krakower, 2012; Mimiaga, 2009; Tripathi, Whiteside, & Duffus, 2013). Possible reasons for low utilization among this higher HIV-risk population include little knowledge about PrEP (Al-Tayyib, Thrun, Haukoos, & Walls, 2014; Galindo, 2012; D. S. Krakower, 2012; Mehta et al, 2011; Rucinski, 2013), barriers to its acquisition and utilization (e.g., costs; concerns about adverse effects, medication use for HIV prevention, or toxicity; concerns about risk compensation; lack of access to healthcare or providers who prescribe PrEP; fears about asking for PrEP; healthcare provider concerns, lack of knowledge, or reluctance to prescribe PrEP) (Bauermeister, Meanley, Pingel, Soler, & Harper, 2013; Brooks et al, 2011; Brooks et al, 2012; Eaton et al, 2014; Golub, Gamarel, Rendina, Surace, & Lelutiu-Weinberger, 2013; Karris, Beekmann, Mehta, Anderson, & Polgreen, 2014; King et al, 2014; D.…”